Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cancer Immunotherapy Via Stem Cell-Derived Nk Cells Publisher Pubmed



Hosseini F1, 2 ; Ahmadvand M3, 4 ; Karimi R5 ; Mousavi SA2 ; Ai J1 ; Nikbakht M2, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, 1417755469, Iran
  2. 2. Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, 1416634793, Iran
  3. 3. Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, 1416634793, Iran
  4. 4. Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, 1411713135, Iran
  5. 5. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, 1417755469, Iran

Source: Immunotherapy Published:2023


Abstract

NK cells are the first sentinels of the immune system that can recognize and eradicate transformed cells. Their activation without a need for additional signaling have attracted great attention on the use of NK cells as a promising option in cancer immunotherapy. However, the large-scale production of NK cells for successful NK cells therapy is a challenge that needs to be tackled. Engineering NK cells to avoid tumor escape and improve their antitumor potency are the other matters of focus that have widely been studied in the recent years. This paper reviews the most recent advances in the stem cell-derived NK cell technology and discusses the potential of the engineered NK cells for clinical applications in cancer immunotherapy. Plain language summary NK cells are important cells in our body's defense system that can find and destroy tumor cells. These cells are made in bone marrow (in adults) or umbilical cord (in the embryonic period) from a population of cells called stem cells, and then released into the blood and lymph. Stem cells are the early ancestral cells that can differentiate into multiple cell types. Because the number and function of NK cells in a tumor context are reduced, thus we can use these stem cells to make lots of NK cells for treatment purposes. Scientists can also make these cells even better at killing tumors by changing them to have special sensors. In the end, NK cells are like superheroes that fight and kill tumor cells, and using stem cells to make them is a really promising way to help treat malignant diseases. © 2023 Future Medicine Ltd.
Other Related Docs
12. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
21. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
23. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
27. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
29. Tumor Immunology, Clinical Immunology (2022)
35. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)